Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Ruvolo

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Haematologica|September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanismsPeter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Oncotarget|November 5, 2017
Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cellsStephen L Abrams, Peter P Ruvolo, Vivian R Ruvolo, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Biochimica Et Biophysica Acta|May 27, 2014
The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cellsPeter P Ruvolo, Vivian R Ruvolo, Rodrigo Jacamo, et al.
Haematologica|March 17, 2018
Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survivalSteven M Kornblau, Peter P Ruvolo, Rui-Yu Wang, et al.
Haematologica|November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemiaSean M Post, Huaxian Ma, Prerna Malaney, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemiaMarina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Cancer Cell|November 14, 2006
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaMarina Konopleva, Rooha Contractor, Twee Tsao, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Haematologica|September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanismsPeter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Oncotarget|November 5, 2017
Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cellsStephen L Abrams, Peter P Ruvolo, Vivian R Ruvolo, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Biochimica Et Biophysica Acta|May 27, 2014
The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cellsPeter P Ruvolo, Vivian R Ruvolo, Rodrigo Jacamo, et al.
Haematologica|March 17, 2018
Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survivalSteven M Kornblau, Peter P Ruvolo, Rui-Yu Wang, et al.
Haematologica|November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemiaSean M Post, Huaxian Ma, Prerna Malaney, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemiaMarina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Cancer Cell|November 14, 2006
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaMarina Konopleva, Rooha Contractor, Twee Tsao, et al.
Pageof 5